Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

E
PII-112
EARLY MEROPENEM PHARMACOKINETICS AND TARGET ATTAINMENT IN CHILDREN WITH SEVERE VS NON-SEVERE SEPSIS

Favorite
PII-036
EFAVIRENZ AND DOLUTEGRAVIR MAY ALTER SIROLIMUS METABOLISM IN PEOPLE WITH HIV

Favorite
CT-002
EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.

Favorite
PII-200
EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.

Favorite
PT-023
EFFECT OF STEROID SPARING IMMUNOSUPPRESSIVE AGENTS USED IN THE TREATMENT OF IMMUNE RELATED ADVERSE EVENTS ON TUMOR OUTCOMES IN MELANOMA AND NON-SMALL CELL LUNG CANCER

Favorite
CT-008
EFFICACY AND SAFETY OF METFORMIN IN TYPE 2 DIABETIC PATIENTS WITH MILD HEPATIC IMPAIRMENTS: A RETROSPECTIVE COHORT STUDY USING PROPENSITY SCORE MATCHING METHOD.

Favorite
PII-201
EFFICACY AND SAFETY OF METFORMIN IN TYPE 2 DIABETIC PATIENTS WITH MILD HEPATIC IMPAIRMENTS: A RETROSPECTIVE COHORT STUDY USING PROPENSITY SCORE MATCHING METHOD.

Favorite
PII-051
ELRANATAMAB INTEGRATED EXPOSURE-RESPONSE (ER) EFFICACY AND SAFETY ANALYSES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) USING A CLINICAL UTILITY INDEX (CUI)

Favorite
PT-019
ESTABLISHING A PARAMOUNT QUANTITATIVE FRAMEWORK LINKING DISEASE PROGRESSION AND CLINICAL OUTCOMES FOR PARKINSONS DISEASE

Favorite
PII-076
ESTIMATED PREVALENCE OF ACTIONABLE EXPOSURES TO PHARMACOGENETIC SUPPORTIVE CARE MEDICATIONS AMONG PATIENTS WITH GASTROINTESTINAL CANCERS.

Favorite
CT-011
ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)

Favorite
PII-052
ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)

Favorite
PII-077
EVALUATING THE ACCURACY OF PHARMACOGENOTYPE EXTRACTION FROM SOMATIC WHOLE EXOME SEQUENCING

Favorite
PII-215
EVALUATING THE EFFICACY OF COMBINATION OF CHECKPOINT INHIBITORS AND CHEMOTHERAPY IN LUNG CANCER USING A MECHANISTIC MODEL

Favorite
TIP-003
EVALUATING THE IMPACT OF XIAO-CHAI-HU-TANG ON PHARMACOKINETIC BEHAVIORS OF IRINOTECAN, RALOXIFENE AND THEIR METABOLITES IN HUMANS: A RUN-IN SAFETY STUDY.

Favorite
PT-015
EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY

Favorite
PWII-002
EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY

Favorite
PII-189
EVALUATION OF CARDIOVASCULAR TOXICITY PROFILE OF ALK INHIBITORS USING ADVERSE EVENT REPORTING DATABASE

Favorite
PII-003
EVALUATION OF DRUG-DRUG INTERACTION (DDI) POTENTIAL FOLLOWING EPCORITAMAB TREATMENT: RESULTS FROM EXPANSION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL.

Favorite
PII-078
EVALUATION OF G6PD ACTIVITY IN ALL OF US

Favorite
PII-114
EVALUATION OF HIGH-DOSE VUTIGLABRIDIN IN HEALTHY PARTICIPANTS: SAFETY, FOOD EFFECT, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS

Favorite
PII-053
EVALUATION OF IMPACT OF PRIOR CAR T THERAPY ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).

Favorite
PT-004
EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.

Favorite
OAII-001
EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.

Favorite
PII-054
EVALUATION OF PHARMACOKINETICS (PK), SERUM CYTOKINES, AND SAFETY FOLLOWING INTRAVENOUS (IV) OR SUBCUTANEOUS (SC) STEP-UP DOSING OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RECURRENT OVARIAN CANCER (OC)

Favorite
PII-010
EVALUATION OF PLASMA BIOMARKERS TO ASSESS THEIR ABILITY TO PREDICT CYP2D6 ACTIVITY IN INDIVIDUALS INCLUDING PATIENTS WITH TYPE 2 DIABETES.

Favorite
LB-013
EVALUATION OF SINGLE DOSE AND STEADY STATE PHARMACOKINETICS AND SAFETY OF AMX0035 IN CAUCASIAN AND JAPANESE HEALTHY MALE AND FEMALE PARTICIPANTS.

Favorite
PII-115
EVALUATION OF THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON ROSUVASTATIN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.

Favorite
PII-169
EVALUATION OF THE POTENTIAL IMPACT ON PHAMACOKINETICS OF VARIOUS CYTOCHROME P450 SUBSTRATES OF INCREASING IL-6 LEVELS FOLLOWING ADMINISTRATION OF THE T-CELL BISPECIFIC ENGAGER GLOFITAMAB

Favorite
PII-020
EVIDENCE FOR INDUCIBLE CMV PROMOTER ACTIVITY IN HUMAN CHONDROCYTES

Favorite
PT-024
EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.

Favorite
PWI-004
EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.

Favorite
PII-033
EXPANDING THE USE OF REAL-WORLD DATA TO ANSWER CLINICAL PHARMACOLOGY QUESTIONS: DEVELOPMENT OF A USER-FRIENDLY DASHBOARD TO ASSESS PREVALENCE OF ORGAN IMPAIRMENT IN PATIENTS IN THE REAL-WORLD SETTING.

Favorite
PII-170
EXPOSURE OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN LACTATING MOTHERS AND THEIR INFANTS: INSIGHTS FROM A PBPK MODEL

Favorite
PII-021
EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)

Favorite
PII-116
EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Favorite
PII-117
EXPOSURE-RESPONSE OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER

Favorite
LB-014
EXTRAPOLATING TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION BETWEEN REMDESIVIR AND CLOFAZIMINE FROM IN VITRO TO IN VIVO: A STATIC APPROACH

Favorite
PII-118
EXTRAPOLATION APPROACH FOR UPADACITINIB IN JUVENILE IDIOPATHIC ARTHRITIS LEVERAGING PHARMACOKINETICS, EXPOSURE-RESPONSE, AND REAL-WORLD PATIENT DATA.

Favorite